PodParley PodParley
PodParley
EASL Studio Podcast: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B: Who will be the winner, if at all? episode artwork

EPISODE · Nov 3, 2022 · 36 MIN

EASL Studio Podcast: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B: Who will be the winner, if at all?

from EASL Podcasts · host European Association for the Study of the Liver

In this JHEP Live the faculty discuss the use of antisense oligonucleotides and siRNAs in the treatment of chronic hepatitis B infections.FacultyProf. Joerg Petersen (Moderator)Prof. Maria Buti (Faculty)Prof. Man-Fung Yuen (Faculty)All EASL Studio Podcasts are available on EASL Campus.

Episode metadata supplied by the publisher feed · Published Nov 3, 2022

Embed this episode

NOW PLAYING

EASL Studio Podcast: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B: Who will be the winner, if at all?

0:00 36:15

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of EASL Podcasts?

This episode is 36 minutes long.

When was this EASL Podcasts episode published?

This episode was published on November 3, 2022.

Can I download this EASL Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!